Drug Trial Radar · NCT06113471
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
Last checked: Nov 20, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Actual
Start
Nov 27, 2023
Primary completion
Mar 17, 2026
Study completion Mar 16, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Nov 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
Conditions
- NonSegmental Vitiligo
Interventions
PovorcitinibDrug
Oral, Tablet
PlaceboDrug
Oral, Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75)Time frame: Week 52
Locations
86 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Hospital-Whitaker Clinic
Birmingham, Alabama
C2 Research Center, Llc
Montgomery, Alabama
First Oc Dermatology Research Inc
Fountain Valley, California
Center For Dermatology Clinical Research, Inc
Fremont, California
Marvel Clinical Research Llc
Huntington Beach, California
Vitiligo & Pigmentation Institute of Southern California
Los Angeles, California
Dermatology Research Associates
Los Angeles, California
Clinical Trials Research Institute
Thousand Oaks, California
Skin Care Research, Llc
Boca Raton, Florida
Total Vein and Skin Llc
Boynton Beach, Florida
Driven Research Llc
Coral Gables, Florida
Florida Academic Centers Research and Education Llc
Coral Gables, Florida
Pediatric Skin Research Llc
Coral Gables, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Dermatology and Surgery Specialists of North Atlanta
Marietta, Georgia
Advanced Medical Research Pc
Sandy Springs, Georgia
Dundee Dermatology
West Dundee, Illinois
Indiana University School of Medicine Iusm Indianapolis
Indianapolis, Indiana
Delricht Research
Baton Rouge, Louisiana
Callender Dermatology and Cosmetic Center
Glenn Dale, Maryland
Aesthetic and Dermatology Center
Rockville, Maryland
Henry Ford Health System
Detroit, Michigan
Allcutis Research, Llc
Portsmouth, New Hampshire
Weill Cornell Medical College
New York, New York
Remington-Davis Clinical Research
Columbus, Ohio
Oregon Medical Research Center, Pc
Portland, Oregon
Dermatology Treatment and Research Center
Dallas, Texas
Heights Dermatology and Aesthetic Center
Houston, Texas
University of Texas, Md Anderson Cancer
Houston, Texas
Innovative Dermatology: Legacy Medical Village
Plano, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
Premier Clinical Research
Spokane, Washington
Medical Center Asklepii Ood
Dupnitsa, Bulgaria
Medical Center Unimed Eood
Sliven, Bulgaria
Ambulatory For Specialized Medical Care - Individual Practice For Specialized Medical Care - Skin An
Sofia, Bulgaria
Aleksandrovska University Hospital
Sofia, Bulgaria
28 Diagnostic and Consultative Center
Sofia, Bulgaria
British Columbia'S Centre For Dermatologic Science - the Skin Care Centre
Vancouver, British Columbia, Canada
Lynderm Research Inc
Markham, Ontario, Canada
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.